7 May 2026

GENinCode Plc

("GENinCode" or the "Company")

Grant of Share Options, Surrender of Existing Options & PDMR Dealings

GENinCode Plc (AIM: GENI), the polygenics company focused on the prevention of cardiovascular disease and ovarian cancer, announces that the Company has approved the grant of options over an aggregate of 83,847,292 new ordinary shares of 1 pence each in the Company ('Ordinary Shares') under the 2021 Share Option Plan ('2021 Share Option Plan') to certain directors and employees of the Company (the "New Options"), representing 11.13 per cent. of the Company's existing issued share capital.

Background to the New Options grants

The Company adopted the 2021 Share Option Plan to enable it to retain and incentivise staff and to reward them for the achievement of its longer-term objectives. The New Options replace 29,856,434 current options ("Existing Options") held by existing option holders, which will be surrendered, and are new grants to those employees who have more recently joined the Group.

Terms of the New Options

The New Options have an exercise price of 1 pence per share and are exercisable on the second anniversary of the date of grant. The New Options will vest over a 24 month period and have a 10-year term.

Surrender of Existing Options

In March 2025, the Company granted options to acquire shares in the capital of the Company to certain employees and directors of the Company pursuant to the 2021 Share Option Plan. These options were granted with an exercise price of 3.7 pence per share.

For directors and employees the existing options will be surrendered for no consideration (the "Option Surrender"), details for which are outlined below. The board believe it is appropriate to issue new share options in replacement of the existing ones to reflect the Company's current share price and to properly incentivise its employees, including its management.

Details of resultant holdings

Following the New Options grant and the Option Surrender, details of options held by Directors, PDMRs and other employees of the Company, are as follows:

Directors and employees of the Group surrendered Options over an aggregate of 29,856,434 Ordinary Shares. The grant of 71,844,958 New Options exercisable at 1 pence to Matthew Walls, Paul Foulger, Jordi Puig, William Rhodes, Huon Gray, Sergio Olivero, and Felix Frueh are intended to replace their surrendered Options.

Following the grant of the New Options and the Options Surrender, there are Options over a total of 85,923,543 Ordinary Shares in the Company as at the date of this announcement, representing approximately 11.41% of the Company's existing issued share capital. 

For more information visit www.genincode.com

Enquiries:

About GENinCode:

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease.

The notification set out below is provided in accordance with the requirements of MAR.